Space Energy Satellite

SpaceX Hits 50 Launches, CRISPR Delivers, and China Eyes Clean Coal

SpaceX logged two milestones over the weekend: the Falcon Heavy returned to flight after an 18-month hiatus, successfully deploying Viasat's final ViaSat-3 broadband satellite from Kennedy Space Center, and the company recorded its 50th Falcon 9 launch of 2026. At that pace, SpaceX is on track for roughly 150 launches this year, a frequency that reflects how dramatically both launch costs and reliability have shifted since commercial spaceflight began.

China's planned 2,800-satellite AI constellation represents a direct challenge to that Western dominance in orbit. Unlike communications satellites, the network is explicitly designed for artificial intelligence applications including real-time data processing and autonomous system coordination — capabilities that, American military planners have noted, could support everything from surveillance to weapons systems guidance.

Chilean astronomers warned that the Atacama Desert's exceptional dark skies remain legally vulnerable to future industrial development despite the cancellation of one major energy project, highlighting the difficulty of protecting irreplaceable scientific assets under existing frameworks. The Atacama hosts some of the world's most advanced telescopes precisely because of its atmospheric conditions, which took millions of years to develop but could be compromised by light pollution in months.

Chinese scientists reported two additional potential breakthroughs: a 'predator' material that reportedly seeks and concentrates uranium from contaminated water, which could make previously uneconomical uranium sources commercially viable and reduce a key constraint on nuclear power expansion; and a zero-emission coal fuel cell that, if scalable, could reshape global energy policy and confer strategic advantages on coal-rich nations. Experts cautioned, however, that the history of energy technology is littered with laboratory successes that failed at commercial scale.

Intellia's Phase 3 CRISPR results — an 87 percent reduction in hereditary angioedema attacks from a single treatment — marked what researchers called the first major clinical success for in vivo gene editing. The result poses a fundamental challenge to pharmaceutical revenue models dependent on lifelong treatment regimens, and is expected to force a rethinking of pricing strategies across the biotech sector.